Royal Philips has received clearance from the U.S. Food and Drug Administration (FDA) for its new detector-based spectral CT radiotherapy (RT) scanner.
The Spectral CT 7500 RT integrates the tumor visualization and tissue characterization capabilities of spectral CT into cancer treatment and planning. The system allows radiation oncologists to target radiation therapy to the specific physiological characteristics of a patient's tumor, which minimizes damage to healthy surrounding tissue and reduces potential unwanted side effects, the company said.
The radiation therapy (RT) scanner is the first to offer respiratory-gated spectral imaging and acquires both true conventional CT and spectral CT information in a single scan. It can also automatically create the SPR (stopping power ratio) map and direct electron density results with less than 1% deviation to enhance both the dose calculation and accuracy of radiotherapy planning, Philips noted.
